Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»315010.69541/NRIPH.2026.01.001Научная статьяEffectiveness of clinical and economic aspects of remote monitoring in patients with diabetes mellitusRyaginaVeronika Anatol`evnaveronika.ryagina.8@gmail.comSuxorukixOl`ga Aleksandrovnasukhorukikh@rosmedex.ruSolyanikEvgenij Anatol`eviche.solyanik@inbox.ruOmel`yanovskijVitalii Vladimirovichoffice@rosmedex.ruIbragimovaLyudmila Ibragimovnaibragimovaliudmila@gmail.comFedyaevDenis Valer`evichfedyaev@nifi.ruZheleznyakovaInna Aleksandrovnajeleznyakova@rosmedex.ruMokry`shevaNatal`ya Georgievnanatalia.mokrysheva@endocrincentr.ruCenter for Healthcare Quality Assessment and Control, Moscow, RussiaN. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russian FederationRussian Medical Academy of Continuous Professional Education, Moscow, RussiaEndocrinology Research Centre, Moscow, Russia23032026151225032026Copyright © 1970,1970Aim: to conduct an assessment of cost-effectiveness of remote monitoring (RM) compared to routine practice (control) in adult patients with type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) on non-insulin therapy, and T2DM on a basal-bolus insulin therapy, based on the results of a multicenter clinical trial (CT) conducted in 2023—2024 in 7 regions of the Russian Federation. Materials and methods: the study consisted of a cost-utility analysis, which included an effectiveness analysis aimed at identifying the effectiveness criterion, the number of years of quality life, as well as an analysis of costs that reflect the current practice of providing medical care to patients with diabetes. Results: according to the results of the cost-effectiveness analysis, which was based on data from a multicenter CT, the cost of an additional year of life adjusted for quality (incremental cost-utility ratio) in adult patients with diabetes mellitus was -96,990,771.23 rubles for RM compared to control with T1DM, and 15,229,158.30 rubles for T2DM on non-insulin therapy. The cost of an added year of life adjusted for quality when using RM in adult patients with T2DM on a basal-bolus insulin regimen was 688,092.98 rubles, which is below the willingness-to-pay threshold (3,530,062.10 rubles in 2024). Conclusion: the results of the clinical and economic evaluation demonstrate the economic feasibility of using RM in patients with T2DM on a basal-bolus insulin regimen.type 1 diabetes, type 2 diabetes, remote monitoring, insulin therapy, clinical and economic studyсахарный диабет 1 типа, сахарный диабет 2 типа, дистанционный мониторинг, инсулинотерапия, клинико-экономическое исследование1.И. И. Дедов, М. В. Шестакова, О. Ю. Сухарева. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 12-й выпуск. М.; 2025. DOI: 10.14341/algdc20252.Дедов И. И., Шестакова М. В., Викулова О. К., и соавт. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010 — 2022 гг. Сахарный диабет. 2023;26(2):104—123. DOI: 10.14341/DM130353.Омельяновский В. В. и др. Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата. Федеральное государственное бюджетное учреждение «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской Федерации. Москва: Наука; 2019.4.Omelyanovskiy V, Musina N, Ratushnyak S, Bezdenezhnykh T, Fediaeva V, Roudijk B, Purba FD. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997—2007. DOI: 10.1007/s11136-021-02804-65.Glick H. A. et al. Economic Evaluation in Clinical Trials. OUP Catalogue. Oxford University Press; 2014.